Compugen: Immuno-Oncology Innovator Poised For A Comeback

Group 1 - Compugen is an under-the-radar player in the biotech industry, focusing on computationally driven drug discovery [1] - The company targets less-known immune pathways such as PVRIG and IL-18 binding protein, differentiating itself from big pharma's focus on familiar checkpoint inhibitors [1] - Compugen is positioned in a sector poised for exponential expansion, indicating potential for high growth [1]